Who ACI is actually for

The most immediate question for anyone researching ACI is straightforward: does my knee damage actually qualify? In England, NHS funding is governed by NICE guidance TA477, published in October 2017, which sets four hard thresholds — and a patient who cannot meet all four is not eligible for NHS-funded treatment.

The criteria work as a checklist:

• Defect size greater than 2 cm² — roughly larger than a 1p coin in cross-section. Smaller focal lesions typically suit other approaches such as OATS or microfracture-based techniques.
• Minimal or no osteoarthritic damage to the surrounding knee joint. Established, diffuse arthritis rules ACI out.
• No previous surgery to repair articular cartilage defects in the same knee. Prior marrow-stimulation procedures, for instance, are associated with higher failure rates and may disqualify a patient.
• Treatment at a commissioned specialist tertiary centre — a small number of NHS hospitals have the cell-manufacturing infrastructure to deliver ACI; it cannot be performed at a standard district general hospital.

Beyond these four gates, conservative treatment — physiotherapy, weight management, structured exercise — must have been tried and found insufficient before ACI is considered.

The procedure is best suited to younger or active patients with an isolated, traumatic focal defect rather than the gradual, diffuse cartilage loss that characterises osteoarthritis. ACI is not a substitute for knee replacement and is explicitly not indicated where widespread joint degeneration is present. Confirming which side of that line a particular case falls on is precisely what a specialist cartilage assessment establishes.

What the two-stage procedure involves

Committing to ACI means committing to two separate operations — and the gap between them surprises many patients.

Stage 1 is a day-case arthroscopy. A small amount of healthy cartilage is harvested from a non-load-bearing area of the knee, and the patient goes home the same day. Those cells are then sent to a specialist laboratory, where they are cultured over several weeks and expand to at least 20 times their original number. The wait between operations — typically a matter of weeks — reflects that culture period; it is not a sign of delay in the pathway.

Stage 2 is open surgery to implant the expanded cell population into the damaged area, where it is secured beneath a periosteal flap. Recovery from this second operation drives the overall timeline. Functional daily use — walking, light work, ordinary movement — typically returns at around three months. Full return to sport or strenuous physical activity generally takes around 12 months. Patients who underestimate that arc sometimes struggle with compliance during the rehabilitation phase, which is central to achieving a good result.

Published success rates position ACI as the gold-standard option for qualifying patients: approximately 85% overall, rising to around 92% for isolated single-lesion defects. Outcomes are less predictable for patients with multiple lesions in the same knee, and evidence suggests that prior marrow-stimulation procedures — such as microfracture — are associated with a higher failure rate. Anyone who has already undergone marrow stimulation in the affected knee should raise this with their surgeon before proceeding, as it may affect candidacy or expected outcome.

How NHS access works — and which centres offer it

Access to NHS-funded ACI is deliberately narrow — and the reason is practical rather than bureaucratic. Producing expanded chondrocytes requires a dedicated cell-manufacturing laboratory, and only a handful of NHS hospitals have that infrastructure in place. As a result, NHS England commissions ACI at a small number of specialist tertiary centres: the Royal National Orthopaedic Hospital (RNOH) in Stanmore, the Robert Jones and Agnes Hunt Orthopaedic Hospital (RJAH) in Oswestry, University Hospital Southampton (UHS), and Sheffield Teaching Hospitals. A standard district general hospital cannot perform the procedure regardless of surgical expertise.

Getting there involves two referral steps. First, a GP or physiotherapist refers the patient to a local NHS orthopaedic consultant. That consultant then assesses whether the patient meets NICE TA477 criteria and, if so, issues a formal consultant-to-consultant tertiary referral to one of the commissioned centres. Self-referral is not available on the NHS pathway; attempting to contact a specialist centre directly will not bypass the process.

NHS funding applies only to patients who satisfy all four NICE criteria. Those who fall outside them — for example, patients with a defect smaller than 2 cm², or who have previously undergone cartilage repair surgery — will not receive NHS-funded ACI regardless of how symptomatic the knee is.

Waiting times at commissioned centres are not reliably published; patients should ask their local orthopaedic consultant for a current estimate once a tertiary referral is in view. For those who do not qualify or prefer not to wait, private access operates under different constraints — covered in the next section.

What ACI costs privately in the UK

Private ACI carries a cost structure unlike most knee procedures, and understanding where the money goes helps explain the total figure.

The dominant expense is not the surgery itself but the cell-culture laboratory work between the two operations. Growing a patient's own chondrocytes to at least 20 times their original number in a specialist facility typically accounts for £10,000–£17,000 of the overall bill. Combined with theatre fees, anaesthesia, and rehabilitation, the total private cost for ACI generally falls in the range of £15,000–£22,000. An initial private consultation to assess suitability typically adds £200–£350 before any treatment begins.

MACI — the matrix-induced variant in which cells are seeded onto a collagen membrane — runs considerably higher, at approximately £25,000–£35,000 privately, and has limited availability from private providers in the UK.

These figures are indicative. Pricing varies between hospitals, and patients should request an itemised quote that specifies theatre, laboratory, implant, and rehabilitation costs separately.

Insurance and payment options

Bupa, AXA Health, and VitalityHealth will generally cover ACI where the consultant deems it medically necessary and prior approval has been obtained. Patients should contact their insurer before committing to any appointment, ask specifically whether ACI is covered under their policy, and confirm that the treating hospital is recognised. A clinical letter from the consulting surgeon setting out the indication is usually required at the approval stage.

Self-funders without insurance cover may be able to spread costs through 0%-interest payment plans running over 10–24 months, which some providers offer. Eligibility for finance arrangements varies and should be confirmed directly with the hospital.

Alternatives for patients who do not qualify for ACI

Not every patient with a symptomatic knee cartilage defect will meet all four NICE criteria — and several evidence-based pathways remain open to those who fall outside ACI's remit.

AMIC (Autologous Membrane-Induced Chondrogenesis) is the most practically accessible alternative for many patients, particularly those seeking private treatment. It is NICE-approved, single-stage, and involves augmenting marrow stimulation with a resorbable scaffold rather than growing cells in a laboratory; scaffold costs of approximately £1,000–£2,000 make the overall private bill substantially lower than ACI, and studies suggest outcomes are broadly comparable.

Microfracture and nano-drilling remain options for smaller defects (typically under 2 cm²), but their role has narrowed considerably — evidence points to fibrocartilage breakdown by around two to three years and a risk of subchondral bone plate damage that can compromise any future repair attempt.

Spherox, a cell therapy delivered at selected NHS centres including the Royal Orthopaedic Hospital in Birmingham, represents an emerging alternative funding pathway worth raising with a referring consultant, though the evidence base is still developing.

MACI follows a similar two-stage cell-based approach to ACI but uses a collagen membrane carrier, and may suit patients who meet ACI-equivalent criteria but are offered this format by their treating centre.

For patients whose primary problem is malalignment or early compartmental osteoarthritis, osteotomy (HTO or DFO) can offload the affected compartment — sometimes combined with a cartilage procedure — to preserve the joint ahead of any replacement.

Finding an ACI specialist in the UK

The most useful preparation before any consultation is a short list of focused questions. For a procedure performed by relatively few surgeons in the UK, volume is the most practical proxy for expertise: how many ACI procedures does the surgeon complete each year? Which certified cell-culture laboratory do they partner with? And what is their personal revision rate? These three questions — on throughput, laboratory quality, and outcomes — give a patient a meaningful basis for comparison that goes beyond reputation alone.

For NHS patients already in the referral pipeline, the next practical step is straightforward: when seeing a local orthopaedic consultant, ask specifically whether NICE TA477 supports a tertiary ACI referral for the presenting defect. Naming the guidance makes the conversation precise and helps avoid a vague 'we'll see' outcome at that appointment.

For those exploring private care, the search should focus on orthopaedic surgeons with specialist cartilage credentials working at centres that combine surgical expertise with a dedicated rehabilitation pathway — post-operative physiotherapy matters as much to long-term outcomes as the implantation itself.

Search MSK is an independent specialist directory listing orthopaedic surgeons across the UK who offer ACI and knee cartilage restoration; use the region and specialty filters to find practitioners near you.

ACI demands a significant commitment of time and, in many cases, money. The five sections above are designed to ensure that commitment is made with clear eyes — and that the first conversation with a specialist is one the patient is equipped to lead.